Small Lymphocytic Lymphoma
📧 Sign up to get email alerts when something new happens for Small Lymphocytic Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-07-01Clinical Trial Update: CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) [Phase 1]
Phase 1 study update for CD19 CAR-allogeneic NKT therapy (ANCHOR) in relapsed or refractory B-cell malignancies; the trial is currently acti…
-
CLINICAL_TRIALS research · 2025-07-01Clinical Trial Update: Allo HSCT Using RIC and PTCy for Hematological Diseases [Phase 2]
Phase 2 clinical trial evaluating allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning and post-transplan…
-
CLINICAL_TRIALS trial_result · 2025-07-01Clinical Trial Update: Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study [Phase 2]
Phase 2 DIRECT trial evaluating daratumumab with ibrutinib for relapsed or refractory chronic lymphocytic leukemia was terminated, with resu…
-
CLINICAL_TRIALS research · 2025-07-01Clinical Trial Update: CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies [Phase 1]
Mayo Clinic is conducting a Phase 1 clinical trial evaluating a CD19-directed CAR-T cell therapy for relapsed/refractory B-cell malignancies…
-
CLINICAL_TRIALS research · 2025-06-27Clinical Trial Update: Combating Cancer-Related Fatigue: A Personalized Supportive Care Program [NA]
This clinical trial update reports a UNC Lineberger Comprehensive Cancer Center study recruiting participants for a personalized supportive …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-06-24Clinical Trial Update: Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Clinical trial update on a Phase 1/2 study of lenalidomide in combination with obinutuzumab for relapsed indolent non-Hodgkin lymphoma, incl…
-
FDA approval · 2025-06-10FDA Approved: BRUKINSA — Original Application (BeOne Medicines USA, Inc.)
The FDA approved the original application for Brukinsa (zanubrutinib) from BeOne Medicines USA, Inc., marking the U.S. approval of this BTK …
-
CLINICAL_TRIALS trial_result · 2025-06-10Clinical Trial Update: Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial of selinexor in combination with ibrutinib for relapsed or refractory chronic lymphocytic leukemia and aggressive non-Hodgkin …
-
CLINICAL_TRIALS withdrawal · 2025-06-05Clinical Trial Update: A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]
A Phase 2 study investigating the sequencing of pirtobrutinib after progression on first-line acalabrutinib in adults with chronic lymphocyt…
-
CLINICAL_TRIALS trial_result · 2025-06-03Clinical Trial Update: A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL [Phase 1]
Phase I study of ONO-4685 as monotherapy to evaluate tolerability and safety in relapsed or refractory T cell lymphoma and chronic lymphocyt…
-
FDA approval · 2025-05-22FDA Approved: LENALIDOMIDE — Original Application (Devatis Inc.)
FDA approved a generic lenalidomide under the original application from Devatis Inc., enabling market access for this established cancer the…
-
CLINICAL_TRIALS withdrawal · 2025-05-16Clinical Trial Update: A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
A clinical trial evaluating a time-limited use of Ibrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma has been withdra…
-
CLINICAL_TRIALS trial_result · 2025-04-24Clinical Trial Update: CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma [Phase 1]
Phase 1 results from a three-drug combination (CC-486/azacitidine, lenalidomide, and obinutuzumab) in patients with recurrent or refractory …
-
CLINICAL_TRIALS trial_result · 2025-04-16Clinical Trial Update: Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL [Phase 1, Phase 2]
A clinical trial is evaluating APG2575 as both a single agent and in combination therapy for relapsed/refractory chronic lymphocytic leukemi…
-
CLINICAL_TRIALS trial_result · 2025-04-10Clinical Trial Update: A Study Of The Selective PKC-β Inhibitor MS- 553 [Phase 1, Phase 2]
A Phase 1/2 study of the selective PKC-β inhibitor MS-553 in chronic lymphocytic leukemia, small lymphocytic lymphoma, and aggressive lympho…
-
CLINICAL_TRIALS research · 2025-04-10Clinical Trial Update: Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL [Phase 1]
This clinical trial update describes a Phase 1 study of APG-2575, studied as a single agent or in combination with other therapies for chron…
-
CLINICAL_TRIALS trial_result · 2025-03-28Clinical Trial Update: Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers [Phase 1]
Aplitabart (IGM-8444) Phase 1a/1b study in solid tumors and various hematologic cancers was terminated.
-
CLINICAL_TRIALS research · 2025-03-14Clinical Trial Update: Study on the Diagnosis and Management of CLL in Italy by GIMEMA
Ongoing Italian study by GIMEMA recruiting to improve diagnosis and management of chronic lymphocytic leukemia and related conditions (inclu…
-
CLINICAL_TRIALS trial_result · 2025-03-07Clinical Trial Update: Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) [Phase 3]
Phase 3 trial comparing pirtobrutinib (LOXO-305) against investigator's choice (idelalisib plus rituximab or bendamustine plus rituximab) in…
-
CLINICAL_TRIALS withdrawal · 2025-03-07Clinical Trial Update: A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas [Phase 1]
A Phase 1 study of CG-806 in relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, and non-Hodgkin's lymphomas ha…
-
FDA approval · 2025-03-03FDA Approved: LENALIDOMIDE — Original Application (BIOCON PHARMA INC.,)
FDA approved Biocon Pharma Inc.'s lenalidomide as an original ANDA, enabling a generic version of the cancer drug. Indications include multi…
-
CLINICAL_TRIALS withdrawal · 2025-02-28Clinical Trial Update: Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation [Phase 1]
Phase 1 trial of ipilimumab, ibrutinib, and nivolumab for chronic lymphocytic leukemia and Richter transformation has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2025-02-27Clinical Trial Update: Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL [Phase 2]
Phase 2 trial evaluating the AU2 combination (acalabrutinib, umbralisib, and ublituximab) in relapsed and untreated chronic lymphocytic leuk…
-
CLINICAL_TRIALS research · 2025-02-24Clinical Trial Update: A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies [Phase 1]
Phase 1 clinical trial update for BP1002 in advanced lymphoid malignancies across several B-cell and T-cell lymphomas; trial status is activ…
-
CLINICAL_TRIALS research · 2025-02-24Clinical Trial Update: A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
This clinical trial update announces a study of lisocabtagene maraleucel for relapsed/refractory Chronic Lymphocytic Leukemia and Small Lymp…